TARS 240920 25.00C (TARS240920C25000) Stock Options, News & Quotes

2.80
-0.50-15.15%

15min DelayClose Aug 30 16:00 ET

3.31High2.80Low

SymbolStock Name

Latest PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

Jaguar8

Aug 8 15:17

NEWS

$Tarsus Pharmaceuticals (TARS.US)$
Tarsus Reports Second Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements
Tarsus Pharmaceuticals (NASDAQ: TARS) reported strong Q2 2024 financial results, with XDEMVY® net product sales reaching $40.8 million, a 65% increase from Q1.
Year-to-date sales totaled $65.5 million.
The company delivered over 37,000 bottles to patients in Q2 and achieved an impressive gross-to-net discount of 44%.
Tarsus expanded payer coverage, incl...

Moomoo AI

Mar 1 12:53

Analysts predict Tarsus Pharmaceuticals' growth to outpace the industry with a 5x annualised growth by 2024. The upgraded price target indicates an expected increase in the business's intrinsic value.

Analysts Are Upgrading Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) After Its Latest Results

Kevin Travers

Feb 27 10:02

Columns Biotechnology Stocks Climbing on Earnings and Test Results: What to Watch

$Viking Therapeutics (VKTX.US)$skyrocketed 77% after positive drug trial news Tuesday, leading to what proved to be a strong morning for pharmaceutical stocks.
Here are some top stocks in the sector climbing on drug trial and earnings news:
$Janux Therapeutics (JANX.US)$shares shot up 205% to $36.00 after the company announced updated clinical data for both of its clinical programs, reaching over $1.50B in market cap.
$Ligand Pharmaceuticals (LGND.US)$gained 23%...

Meltyy

Jan 24 03:25

Ph2 readouts in Q1 2024...

$Pfizer (PFE.US)$ Phase 2
$Leap Therapeutics (LPTX.US)$ Phase 2
$Vera Therapeutics (VERA.US)$ Phase 2b
$4D Molecular Therapeutics (FDMT.US)$ Phase 2
$Adverum Biotechnologies (ADVM.US)$ Phase 2
$Denali Therapeutics (DNLI.US)$ Phase 2
$Akero Therapeutics (AKRO.US)$ Phase 2b
$Spruce Biosciences (SPRB.US)$ Phase 2
$Xencor (XNCR.US)$ Phase 2
$Alnylam Pharmaceuticals (ALNY.US)$ Phase 2
$Harmony Biosciences (HRMY.US)$ Phase 2
$Annexon (ANNX.US)$ Phase 2a
$Roivant Sciences (ROIV.US)$...

Moomoo AI

Jan 12 06:52

Insider transactions at Tarsus Pharmaceuticals over the past year are not encouraging. Despite insiders owning shares, the net investment doesn't inspire much confidence.

Tarsus Pharmaceuticals Insiders Benefitted From Selling Stock At US$12.72